Supernus Pharmaceuticals Inc
LSE:0LB2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
A
|
American Electric Power Company Inc
F:AEP
|
US |
|
M
|
ManpowerGroup Inc
XMUN:MPW
|
US |
|
Canal+ SA
F:YA3
|
FR |
|
P
|
PICC Property and Casualty Co Ltd
XMUN:PJC
|
CN |
|
EMCOR Group Inc
NYSE:EME
|
US |
|
Matas A/S
CSE:MATAS
|
DK |
|
Assicurazioni Generali SpA
F:ASG
|
IT |
|
C
|
Compass Minerals International Inc
F:CM8
|
US |
|
D'Ieteren Group NV
F:DJD
|
BE |
Wall St Price Targets
0LB2 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0LB2 is 64.81 USD with a low forecast of 56.38 USD and a high forecast of 71.41 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0LB2's stock price target?
Price Target
64.81
USD
According to Wall Street analysts, the average 1-year price target for 0LB2 is 64.81 USD with a low forecast of 56.38 USD and a high forecast of 71.41 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
